This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mesoblast Selects Medidata’s Cloud-based Clinical Research Platform To Accelerate Cutting-edge Stem Cell Research

Medidata Solutions (NASDAQ: MDSO) continues to lead the market with its cloud-based clinical development platform through a new customer commitment from Mesoblast Limited, a world leader in developing biologic products for the broad field of regenerative medicine. Mesoblast will implement Medidata Rave ®, including Rave Safety Gateway and Rave Targeted SDV, and Medidata Coder™ across its clinical studies to support the development of treatments based on its proprietary adult stem cell technology.

Medidata’s platform is seen as a cost-efficient solution to improve Mesoblast’s clinical trial efficiencies across multiple therapeutic areas, to effectively monitor and control risks, and to streamline trial execution to meet tight deadline goals.

Medidata Rave, a leading electronic data capture (EDC) and clinical data management (CDM) solution, enables real-time visibility into clinical trial data. The flexibility of Rave allows Mesoblast to proactively adjust a trial’s data validation plan and management processes, and also apply learnings to other studies in a timely fashion to improve trial quality and efficiency.

Mesoblast selected Rave for its superior user experience and comprehensive functionality. The context-sensitive, on-screen help minimizes the dependence on calling help desks and eliminates delays in entering and cleaning data. Moreover, research sites’ familiarity with Rave will help Mesoblast to expedite site initiation.

Further building out the clinical trial process, Mesoblast selected Rave Targeted SDV to reduce site monitoring costs through a risk-based approach. The implementation of Rave Safety Gateway and Medidata Coder will enable Mesoblast to increase the efficiency of its safety reporting process.

  • “Mesoblast chose Medidata Solutions for our ability to drive improved efficiency and more effective decision making across their trials process,” said Tarek Sherif, CEO, Medidata Solutions. “We’re very excited that the Medidata Clinical Cloud is playing a key role in allowing Mesoblast to execute at the forefront of regenerative medicine research and adult stem cell technology.”

Connect with Medidata:

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs